CN112807275B - Ophthalmic composition and preparation method and application thereof - Google Patents
Ophthalmic composition and preparation method and application thereof Download PDFInfo
- Publication number
- CN112807275B CN112807275B CN201911120990.1A CN201911120990A CN112807275B CN 112807275 B CN112807275 B CN 112807275B CN 201911120990 A CN201911120990 A CN 201911120990A CN 112807275 B CN112807275 B CN 112807275B
- Authority
- CN
- China
- Prior art keywords
- ophthalmic composition
- olopatadine
- ganciclovir
- ophthalmic
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
The present invention relates to an ophthalmic composition comprising ganciclovir and olopatadine; wherein the mass ratio of the ganciclovir to the olopatadine is (2-6): 1. The invention also relates to a preparation method of the ophthalmic composition, which comprises the following steps: step S1, mixing ganciclovir, olopatadine, osmotic pressure regulator, pH regulator and water for injection at the temperature of 90-100 ℃ to obtain a mixed solution; and step S2, adding a solubilizer, a preservative and water for injection into the mixed solution at the temperature of 70-80 ℃ to obtain the ophthalmic composition. In addition, the invention also relates to application of the ophthalmic composition in preparing a medicament for treating keratitis. The eye drops containing the ophthalmic composition provided by the invention not only have good anti-inflammatory and antiviral effects, but also can avoid adverse reaction symptoms such as eyelid edema, conjunctival congestion, pain, burning sensation and the like of a patient after long-term use.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to an ophthalmic composition, and a preparation method and application thereof.
Background
The viral keratitis is caused by the infection of herpes simplex type I virus of herpesviridae, is a common multiple disease seriously harming human eye health, the blindness rate of an uncured person is extremely high, and nearly 500 ten thousand patients in China cause blindness or vision deterioration due to the viral keratitis infection every year. The existing antiviral eye drugs such as idodine, cytarabine, cyclocytidine and the like are easy to generate drug resistance or obvious adverse reactions. Although the ganciclovir eye drops as an antiviral drug has good spectrum bacteriostasis, adverse reaction symptoms such as eyelid edema, conjunctival congestion, pain, burning sensation and the like can be caused to a patient after the ganciclovir eye drops are used for a long time.
Therefore, the problem at present is to provide an ophthalmic composition capable of preventing adverse reaction symptoms of eyes of patients, and a preparation method and application thereof.
Disclosure of Invention
Aiming at the defects in the prior art, the invention aims to provide an ophthalmic composition and a preparation method and application thereof. The ophthalmic composition comprises ganciclovir and olopatadine. The eye drops containing the ophthalmic composition provided by the invention not only have good anti-inflammatory and antiviral effects, but also can avoid adverse reaction symptoms such as eyelid edema, conjunctival congestion, pain, burning sensation and the like of a patient after long-term use.
To achieve the above object, the present invention provides in a first aspect an ophthalmic composition comprising ganciclovir and olopatadine; wherein the mass ratio of the ganciclovir to the olopatadine is (2-6): 1.
In some specific embodiments of the present invention, the mass ratio of ganciclovir to olopatadine is 2:1 or 3:1 or 4:1 or 5:1 or 6:1 or a range consisting of any two of them.
According to the present invention, the ophthalmic composition further comprises an adjuvant; the auxiliary agent comprises an osmotic pressure regulator, a solubilizer, a preservative, a pH regulator and water for injection.
In some specific embodiments of the present invention, the ophthalmic composition comprises, based on the total weight of the ophthalmic composition:
in some preferred embodiments of the present invention, the ophthalmic composition comprises, based on the total weight of the ophthalmic composition:
according to the present invention, the osmotic pressure regulator includes at least one of sodium chloride, mannitol, potassium chloride, glycerin, sorbitol, glucose, and propylene glycol.
According to the present invention, the solubilizer includes at least one of polysorbate-80, poloxamer, hydroxypropyl- β -cyclodextrin, and polyethylene glycol-12-hydroxystearate.
According to the invention, the preservative comprises at least one of benzalkonium chloride, benzalkonium bromide, sorbic acid, methylparaben, ethylparaben, benzoic acid and benzyl alcohol.
According to the invention, the pH regulator comprises at least one of citric acid, sodium citrate, sodium hydroxide, boric acid and borax. Preferably, the pH adjuster comprises boric acid and borax. More preferably, the content of the boric acid is 0.15 wt% to 0.38 wt% and the content of the borax is 0.12 wt% to 0.35 wt%, based on the total weight of the ophthalmic composition.
In a second aspect, the present invention provides a method for preparing an ophthalmic composition according to the first aspect of the present invention, comprising the steps of:
step S1, mixing ganciclovir, olopatadine, osmotic pressure regulator, pH regulator and water for injection at the temperature of 90-100 ℃ to obtain a mixed solution;
step S2, adding solubilizer, preservative and water for injection into the mixed solution at the temperature of 70-80 ℃ to obtain the ophthalmic composition;
wherein the ratio of the dosage of the water for injection in the step S1 to the dosage of the water for injection in the step S2 is (2-3): 1.
In the present invention, the mixing temperature of step S1 is controlled to be higher than the mixing temperature of step S2 in order to prevent the solubilizer from being decomposed by heat.
In a third aspect, the present invention provides a use of the ophthalmic composition according to the first aspect of the present invention or the ophthalmic composition prepared by the method according to the second aspect of the present invention in the preparation of a medicament for treating keratitis, wherein the medicament comprises the ophthalmic composition, and the medicament is an eye drop.
Compared with the prior art, the invention has the beneficial effects that:
the eye drops containing the eye composition have good anti-inflammatory and antiviral effects, and adverse reaction symptoms such as eyelid edema, conjunctival congestion, pain, burning sensation and the like of a patient caused by long-term use can be avoided.
Detailed Description
In order that the invention may be more readily understood, reference will now be made in detail to the following examples. It is to be understood that these examples are illustrative only and are not intended to limit the present invention.
EXAMPLES preparation of ophthalmic composition and quality control of eye drops
Example 1
(1) Preparation of ophthalmic compositions
Add a prepared total of 2/3 of water for injection to the dosage tank and turn on the stirring. Adding ganciclovir, olopatadine, sodium chloride (osmotic pressure regulator), borax and boric acid (pH regulator) into a dosing tank at the temperature of 65 ℃, stirring until the mixture is completely dissolved, heating to 99 ℃, keeping the temperature and stirring for 15 minutes, cooling to 80 ℃, adding benzalkonium chloride (preservative) solution and polysorbate-80 solubilizer (), stirring until the mixture is completely dissolved, cooling to room temperature, and fixing the volume to the full volume to obtain the ophthalmic composition which is prepared from the following components in percentage by weight of the total weight of the ophthalmic composition:
(2) quality test of eye drops
The ophthalmic composition prepared in example 1 is used as eye drops, accelerated stability inspection is performed according to the principle of stability inspection of preparations in 'Chinese pharmacopoeia' 2015 version 9001, and meanwhile, related indexes are inspected according to the requirements under the general rule of 0105 ophthalmic preparations, and the specific inspection method is as follows:
the pH, osmotic pressure and microorganism test of the eye drops are respectively tested according to the methods under the items of 'Chinese pharmacopoeia' 2015 edition 0631, 0632 and 3300.
The content of ganciclovir and olopatadine are respectively tested according to the method carried in the second part of the 'Chinese pharmacopoeia' 2015 edition.
Table 1 test results of ophthalmic composition of example 1 as eye drops
As can be seen from table 1, the ophthalmic composition prepared in example 1 of the present invention meets the quality standard requirements of the ophthalmic formulation in pharmacopeia, and other components have good compatibility with ganciclovir or olopatadine and do not interact.
Example 2
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this example was prepared as in example 1, and had the following composition, based on the total weight of the ophthalmic composition:
(2) quality test of eye drops
The ophthalmic composition prepared in example 2 was used as eye drops and tested according to the test method described in example 1 while accelerated stability test was conducted according to the principle of stability test of formulation 9001 in "Chinese pharmacopoeia" 2015 edition, and the results are shown in Table 2.
Table 2 test results of ophthalmic composition of example 2 as eye drops
As can be seen from table 2, the ophthalmic composition prepared in example 2 of the present invention meets the quality standard requirements of the ophthalmic formulation in pharmacopeia, and other components have good compatibility with ganciclovir or olopatadine and do not interact.
Example 3
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this example was prepared as in example 1, and had the following composition, based on the total weight of the ophthalmic composition:
(2) quality test of eye drops
The ophthalmic composition prepared in example 3 was used as eye drops and tested according to the test method described in example 1 while accelerated stability test was conducted according to the principle of stability test of formulation 9001 in "Chinese pharmacopoeia" 2015 edition, and the results are shown in Table 3.
Table 3 test results of ophthalmic composition of example 3 as eye drops
As can be seen from table 3, the ophthalmic composition prepared in example 3 of the present invention meets the quality standard requirements of the pharmacopeia ophthalmic formulation, and other components have good compatibility with ganciclovir or olopatadine and do not interact.
Example 4
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this example was prepared as in example 1, except that the osmotic pressure regulator was glycerol, the solubilizer was hydroxypropyl- β -cyclodextrin, the preservative was cresyl, and the pH regulator was boric acid. The composition of the ophthalmic composition based on the total weight of the ophthalmic composition is as follows:
(2) quality test of eye drops
The ophthalmic composition prepared in example 4 was used as eye drops and tested according to the test method described in example 1 while accelerated stability test was conducted according to the principle of stability test of formulation 9001 in "Chinese pharmacopoeia" 2015 edition, and the results are shown in Table 4.
Table 4 test results of ophthalmic composition of example 4 as eye drops
As can be seen from table 4, the ophthalmic composition prepared in example 4 of the present invention meets the quality standard requirements of the pharmacopeia ophthalmic formulation, and other components have good compatibility with ganciclovir or olopatadine and do not interact.
Example 5
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this example was prepared as in example 1, except that the solubilizer was ethylene glycol-12-hydroxystearate, the preservative was benzyl alcohol, and the pH adjuster was sodium citrate. The composition of the ophthalmic composition based on the total weight of the ophthalmic composition is as follows:
(2) quality test of eye drops
The ophthalmic composition prepared in example 5 was used as eye drops and tested according to the test method described in example 1 while accelerated stability test was conducted according to the principle of stability test of formulation 9001 in "Chinese pharmacopoeia" 2015 edition, and the results are shown in Table 5.
TABLE 5 examination results of the ophthalmic composition of example 5 as eye drops
As can be seen from table 5, the ophthalmic composition prepared in example 5 of the present invention meets the quality standard requirements of the pharmacopeia ophthalmic formulation, and other components have good compatibility with ganciclovir or olopatadine and do not interact.
Example 6
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this example was prepared in the same manner as in example 1, except that the osmotic pressure adjusting agent was glycerin, the preservative was methylparaben, and the pH adjusting agent was borax. The composition of the ophthalmic composition based on the total weight of the ophthalmic composition is as follows:
(2) quality test of eye drops
The ophthalmic composition prepared in example 6 was used as eye drops and tested according to the test method described in example 1 while accelerated stability test was conducted according to the principle of stability test of formulation 9001 in "Chinese pharmacopoeia" 2015 edition, and the results are shown in Table 6.
Table 6 test results of ophthalmic composition of example 6 as eye drops
As can be seen from table 6, the ophthalmic composition prepared in example 6 of the present invention meets the quality standard requirements of the pharmacopeia ophthalmic formulation, and other components have good compatibility with ganciclovir or olopatadine and do not interact.
Example 7
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this example was prepared in the same manner as in example 1, except that the osmotic pressure regulator was propylene glycol, the solubilizer was poloxamer, the preservative was ethylparaben, and the pH regulator was boric acid. The composition of the ophthalmic composition based on the total weight of the ophthalmic composition is as follows:
(2) quality test of eye drops
The ophthalmic composition prepared in example 7 was used as eye drops and tested according to the test method described in example 1 while accelerated stability test was conducted according to the principle of stability test of formulation 9001 in "Chinese pharmacopoeia" 2015 edition, and the results are shown in Table 7.
Table 7 test results of ophthalmic composition of example 7 as eye drops
As can be seen from table 7, the ophthalmic composition prepared in example 7 of the present invention meets the quality standard requirements of the pharmacopeia ophthalmic formulation, and other components have good compatibility with ganciclovir or olopatadine and do not interact.
Comparative example 1
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this comparative example was prepared in the same manner as in example 1, except that olopatadine was not added. The composition of the ophthalmic composition based on the total weight of the ophthalmic composition is as follows:
(2) quality test of eye drops
The ophthalmic composition prepared in comparative example 1 was used as eye drops and subjected to accelerated stability examination according to the principle of stability examination of formulations in "Chinese pharmacopoeia" 2015 edition 9001, and examined according to the examination method described in example 1, and the results are shown in Table 8.
TABLE 8 examination results of the ophthalmic composition of comparative example 1 as eye drops
As can be seen from Table 8, the ophthalmic composition prepared in comparative example 1 of the present invention meets the quality standard requirements of pharmacopoeia for ophthalmic preparations.
Comparative example 2
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this comparative example was prepared as in example 1, except that ganciclovir was not added. The composition of the ophthalmic composition based on the total weight of the ophthalmic composition is as follows:
(2) quality test of eye drops
The ophthalmic composition prepared in comparative example 2 was used as eye drops and subjected to accelerated stability examination according to the principle of stability examination of formulations in "Chinese pharmacopoeia" 2015 edition 9001, and examined according to the examination method described in example 1, and the results are shown in Table 9.
TABLE 9 examination results of the ophthalmic composition of comparative example 2 as eye drops
As can be seen from Table 9, the ophthalmic composition prepared by the comparative example 2 of the present invention satisfies the quality standard requirements of the pharmacopoeia for ophthalmic preparations.
Comparative example 3
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this comparative example was prepared in the same manner as in example 1. The composition of the ophthalmic composition based on the total weight of the ophthalmic composition is as follows:
(2) quality test of eye drops
The ophthalmic composition prepared in comparative example 3 was used as eye drops and subjected to accelerated stability examination in accordance with the principle of stability examination of formulations in "Chinese pharmacopoeia" 2015 edition 9001 and examined in accordance with the examination method described in example 1, and the results are shown in Table 10.
TABLE 10 examination results of the ophthalmic composition of comparative example 3 as eye drops
As can be seen from Table 10, the ophthalmic composition prepared in comparative example 3 of the present invention meets the quality standard requirements of ophthalmic preparations in pharmacopeia, and other components have good compatibility with ganciclovir or olopatadine and do not interact.
Comparative example 4
(1) Preparation of ophthalmic compositions
The ophthalmic composition of this comparative example was prepared in the same manner as in example 1. The composition of the ophthalmic composition based on the total weight of the ophthalmic composition is as follows:
(2) quality test of eye drops
The ophthalmic composition prepared in comparative example 4 was used as eye drops, and accelerated stability examination was performed according to the principle of stability examination of formulations in "chinese pharmacopoeia" 2015 version 9001, and the results of examination were shown in table 11, according to the test method described in example 1.
TABLE 11 examination results of the ophthalmic composition of comparative example 4 as eye drops
As can be seen from Table 11, the ophthalmic composition prepared in comparative example 4 of the present invention meets the quality standard requirements of ophthalmic preparations in pharmacopeia, and other components have good compatibility with ganciclovir or olopatadine and do not interact.
Animal experiments
Selecting 120 Wistar rats with male and female halves and weight of 80-120g, randomly dividing the Wistar rats into 12 groups, each group containing 10 rats, wherein 1 group is a control group, and the rest 11 groups are experimental groups. Each group was modeled for conjunctivitis: the mouse head was fixed, the face was pulled down, and 200. mu.l of 10 wt% croton oil-based inflammatory agent was dropped into each eye, and the solution was left in the conjunctival sac for 45 seconds and washed away with physiological saline. After 1h of successful inflammation, injection water is respectively dripped into a control group, and the ophthalmic compositions of the examples 1-7 and the comparative examples 1-4 are respectively dripped into the experimental group for 2-3 drops every time for 1 day twice. According to ocular inflammatory manifestations: lacrimation, viscous secretion, conjunctival congestion, edema and corneal edema, observing whether the cornea, iris and conjunctiva are eyelid edema, conjunctival congestion and pain burning sensation with naked eyes or by using a slit lamp at different times after the application of the medicine, and scoring, wherein the scoring standard is shown in table 12 (CN102670494B), then calculating the total score according to the scoring standard, judging the irritation according to the total score, wherein the judging standard is shown in table 13, calculating the average score (═ total score/5), and the evaluation result is shown in table 14.
TABLE 12 Scoring criteria
TABLE 13 irritation criteria
| Score value | 0-3 | 4-8 | 9-12 | 13-16 |
| Evaluation of | Has no irritation | Mild stimulation | Moderate stimulation | Stimulation of intensity |
TABLE 14 evaluation results
As can be seen from Table 14, 3 days after administration, the eye irritation symptoms of examples 1-7 disappeared, congestion disappeared, corneal ulcer was repaired, edema disappeared, and the wrinkles of the elastic layer disappeared, while the eye inflammation disappeared more slowly in comparative example 1, mainly due to its adverse reactions, while olopatadine in comparative example 2 did not produce antiviral and anti-inflammatory effects, and thus did not improve, while the prescription ratio of ganciclovir to olopatadine in ratios 3-4 did not allow the eye to recover quickly.
In conclusion, the medicinal composition for eyes provided by embodiments 1 to 7 of the invention is combined with more piroxicam and olopatadine, so that the medicinal composition has synergistic effect, the curative effect on conjunctivitis is improved, the medicinal composition has good curative effect on congestion, edema and the like caused by inflammation, the side effect of the medicinal composition can be obviously reduced, and the medication compliance of patients is improved. Meanwhile, the antibacterial agent has a certain antibacterial effect, can kill germs, and further improves the treatment effect.
The present invention is not limited to the above-described embodiments, and it will be apparent to those skilled in the art that various modifications and improvements can be made without departing from the principle of the present invention, and such modifications and improvements are also considered to be within the scope of the present invention. What is not described in detail in this specification is prior art to the knowledge of those skilled in the art.
Claims (8)
1. An ophthalmic composition comprising ganciclovir and olopatadine; wherein the mass ratio of the ganciclovir to the olopatadine is (2-6): 1;
the ophthalmic composition comprises, based on the total weight of the ophthalmic composition:
ganciclovir 0.1-0.4 wt%;
olopatadine 0.05wt% -0.07 wt%;
0.1-0.5 wt% of osmotic pressure regulator;
0.05wt% -0.2wt% of solubilizer;
0.05wt% -0.25wt% of preservative;
0.1-0.86 wt% of pH regulator; and the remainder of
Water for injection.
2. The ophthalmic composition of claim 1, wherein the ophthalmic composition comprises, based on the total weight of the ophthalmic composition:
ganciclovir 0.2-0.3 wt%;
olopatadine 0.05wt% -0.06 wt%;
0.1-0.4 wt% of osmotic pressure regulator;
0.05wt% -0.2wt% of solubilizer;
0.05wt% -0.25wt% of preservative;
0.1-0.71 wt% of pH regulator; and the remainder of
Water for injection.
3. The ophthalmic composition of claim 1, wherein the tonicity adjusting agent includes at least one of sodium chloride, mannitol, potassium chloride, glycerin, sorbitol, dextrose, and propylene glycol.
4. The ophthalmic composition of claim 1, wherein the solubilizing agent comprises at least one of polysorbate-80, poloxamer, hydroxypropyl- β -cyclodextrin, and polyethylene glycol-12-hydroxystearate.
5. The ophthalmic composition of claim 1 wherein the preservative comprises at least one of benzalkonium chloride, benzalkonium bromide, sorbic acid, methylparaben, ethylparaben, benzoic acid, and benzyl alcohol.
6. The ophthalmic composition of claim 1, wherein the pH adjusting agent comprises at least one of citric acid, sodium citrate, sodium hydroxide, boric acid, and borax.
7. A method of making an ophthalmic composition according to any one of claims 1-6, comprising the steps of:
step S1, mixing ganciclovir, olopatadine, osmotic pressure regulator, pH regulator and water for injection at the temperature of 90-100 ℃ to obtain a mixed solution;
step S2, adding solubilizer, preservative and water for injection into the mixed solution at the temperature of 70-80 ℃ to obtain the ophthalmic composition;
wherein the ratio of the dosage of the water for injection in the step S1 to the dosage of the water for injection in the step S2 is (2-3): 1.
8. Use of an ophthalmic composition according to any one of claims 1 to 6 or prepared according to the method of claim 7 in the preparation of a medicament for the treatment of conjunctivitis; wherein, the medicine is eye drops.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911120990.1A CN112807275B (en) | 2019-11-15 | 2019-11-15 | Ophthalmic composition and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911120990.1A CN112807275B (en) | 2019-11-15 | 2019-11-15 | Ophthalmic composition and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112807275A CN112807275A (en) | 2021-05-18 |
| CN112807275B true CN112807275B (en) | 2022-05-20 |
Family
ID=75852911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911120990.1A Active CN112807275B (en) | 2019-11-15 | 2019-11-15 | Ophthalmic composition and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112807275B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020098154A1 (en) * | 2001-01-20 | 2002-07-25 | Dyer Gordon Wayne | Methods and apparatus for medicating the nasal sinuses |
| CN1939277A (en) * | 2005-09-30 | 2007-04-04 | 庄臣及庄臣视力保护公司 | Methods for stabilizing ophthalmic compositions |
| CN102342911A (en) * | 2011-10-09 | 2012-02-08 | 南京恒道医药科技有限公司 | Ganciclovir eye drops and preparation method thereof |
| CN104144690A (en) * | 2011-11-24 | 2014-11-12 | 东洋精糖株式会社 | Keratoconjunctival protecting agent, or keratoconjunctival disorder inhibiting agent |
| EP2979689A1 (en) * | 2014-07-29 | 2016-02-03 | Sygene Technologies | Composition for an eye drop and delivery system therefor |
| CN105349492A (en) * | 2011-05-18 | 2016-02-24 | 加利福尼亚大学董事会 | Compositions and methods for treating retinal diseases |
| US20180193348A1 (en) * | 2013-01-29 | 2018-07-12 | Lily Hsiao | Medicament for Treating Peripheral Neuropathies |
| CN110013498A (en) * | 2019-05-10 | 2019-07-16 | 合肥华威药业有限公司 | A kind of eye drops and preparation method thereof of hydrochloric olopatadine |
-
2019
- 2019-11-15 CN CN201911120990.1A patent/CN112807275B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020098154A1 (en) * | 2001-01-20 | 2002-07-25 | Dyer Gordon Wayne | Methods and apparatus for medicating the nasal sinuses |
| CN1939277A (en) * | 2005-09-30 | 2007-04-04 | 庄臣及庄臣视力保护公司 | Methods for stabilizing ophthalmic compositions |
| CN105349492A (en) * | 2011-05-18 | 2016-02-24 | 加利福尼亚大学董事会 | Compositions and methods for treating retinal diseases |
| CN102342911A (en) * | 2011-10-09 | 2012-02-08 | 南京恒道医药科技有限公司 | Ganciclovir eye drops and preparation method thereof |
| CN104144690A (en) * | 2011-11-24 | 2014-11-12 | 东洋精糖株式会社 | Keratoconjunctival protecting agent, or keratoconjunctival disorder inhibiting agent |
| US20180193348A1 (en) * | 2013-01-29 | 2018-07-12 | Lily Hsiao | Medicament for Treating Peripheral Neuropathies |
| EP2979689A1 (en) * | 2014-07-29 | 2016-02-03 | Sygene Technologies | Composition for an eye drop and delivery system therefor |
| CN110013498A (en) * | 2019-05-10 | 2019-07-16 | 合肥华威药业有限公司 | A kind of eye drops and preparation method thereof of hydrochloric olopatadine |
Non-Patent Citations (1)
| Title |
|---|
| 0.1%奥洛他定滴眼液治疗过敏性结膜炎的疗效观察;王文娟等;《江西医学院学报》;20091231;第49卷;第11-12页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112807275A (en) | 2021-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3310079C2 (en) | ||
| CN102078284B (en) | Gatifloxacin-containing gel for eyes and preparation method thereof | |
| DE2708152A1 (en) | PHARMACEUTICAL CARRIERS AND THEIR USE | |
| JP6994061B2 (en) | Preparation of 4- (7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3-yl) -benzonitrile | |
| WO2021017475A1 (en) | Ophthalmic pharmaceutical composition containing cyclosporine, preparation method and use thereof | |
| CN110974970A (en) | Compound pharmaceutical composition eye drops, preparation method and application thereof | |
| CN112823020A (en) | Ophthalmic compositions for treating dry eye | |
| EP0517160B1 (en) | Extended-release ophthalmic preparations | |
| CN102085203B (en) | Ophthalmic preparation of levofloxacin and prednisolone acetate and preparation method thereof | |
| CN1302812C (en) | Transmission system of medicine containing trehalose and hyaluronic acid for eye part and its preparation method | |
| CN112807275B (en) | Ophthalmic composition and preparation method and application thereof | |
| JP2009509993A (en) | A photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis | |
| CN103977011A (en) | Travoprost and timolol-containing ophthalmic gel and preparation method thereof | |
| JP2014521606A (en) | Compositions and methods for the treatment of ocular surface allergies | |
| KR20160096376A (en) | Ophthalmic composition comprising hyaluronic acid, mineral oil and surfactants | |
| TW201815397A (en) | Ophthalmic agent and ophthalmologic drug | |
| CN109453151B (en) | Pharmaceutical composition for eyes, preparation method and application thereof | |
| El-Kateb et al. | Epithelium-off versus epithelium-on corneal collagen cross-linking with accelerated UV− a protocol for treatment of keratoconus | |
| CN112263545B (en) | Ophthalmic composition and preparation method and application thereof | |
| CN110876746B (en) | Ginkgo diterpene lactone eye preparation and preparation method and application thereof | |
| CN111905094B (en) | Ophthalmic composition and application thereof in preparation of medicine for treating xerophthalmia | |
| CN114099505B (en) | Ophthalmic composition, preparation method and application thereof | |
| CN101579498A (en) | Ready-to-use zedoary turmeric oil ophthalmic gel | |
| US20230372236A1 (en) | Drug containing dissolvable ocular inserts and method of using same | |
| CN109549922B (en) | Topiramide ophthalmic composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |